Comparison of single agent versus combination activity of enfortumab vedotin (EV) and sacituzumab govitecan (SG) in a panel of bladder cancer XPDX models - Simonson, A; Flores, J; Mercer, G; Lopez, M; Garcia, R; Lund, J; Banos, N; Papadopoulos, K; Calvo, E; Pedregal, M; Hernandez, T; Rasco, D; et al. (European Journal Of Cancer, 2024)